IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by National Pension Service

National Pension Service grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 165,614 shares of the company’s stock after acquiring an additional 3,679 shares during the period. National Pension Service’s holdings in IDEXX Laboratories were worth $91,924,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Blair William & Co. IL lifted its holdings in IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock worth $524,700,000 after buying an additional 7,812 shares during the last quarter. Morgan Stanley lifted its holdings in shares of IDEXX Laboratories by 4.7% in the 3rd quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock valued at $465,482,000 after purchasing an additional 48,095 shares during the last quarter. Northern Trust Corp increased its position in IDEXX Laboratories by 7.7% in the 3rd quarter. Northern Trust Corp now owns 919,191 shares of the company’s stock valued at $401,935,000 after acquiring an additional 65,891 shares during the period. Principal Financial Group Inc. increased its position in IDEXX Laboratories by 1.4% in the 3rd quarter. Principal Financial Group Inc. now owns 815,863 shares of the company’s stock valued at $356,753,000 after acquiring an additional 11,315 shares during the period. Finally, JPMorgan Chase & Co. increased its position in IDEXX Laboratories by 8.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 801,274 shares of the company’s stock valued at $350,373,000 after acquiring an additional 65,760 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on IDXX shares. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research note on Tuesday, January 30th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $580.88.

IDEXX Laboratories Trading Up 2.6 %

Shares of IDXX stock traded up $12.50 on Thursday, reaching $499.57. 194,633 shares of the stock were exchanged, compared to its average volume of 440,961. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The stock has a market cap of $41.26 billion, a P/E ratio of 48.21, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $519.60 and a two-hundred day moving average of $514.34.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. During the same period in the prior year, the firm earned $2.05 EPS. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.05 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.